The impact of folate status on the efficacy of colorectal cancer treatment

Current Drug Metabolism

Volumn 12, Issue 10, 2011, Pages 975-984

  Porcelli, Letizia ^a,c   Assaraf, Yehuda G ^b   Azzariti, Amalia ^a   Paradiso, Angelo ^a   Jansen, Gerrit ^c   Peters, Godefridus J ^c  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal cancer; Drug resistance; Folate status; Preclinical and clinical studies

Indexed keywords

ANTIMETABOLITE; CISPLATIN; DEOXYURIDINE PHOSPHATE; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLYLPOLYGLUTAMATE SYNTHASE; METHOTREXATE; S ADENOSYLMETHIONINE; TETRAHYDROFOLIC ACID;

ALLELE; ARTICLE; CANCER THERAPY; COLORECTAL CANCER; DNA METHYLATION; DRUG MECHANISM; FOLATE METABOLISM; HUMAN; INTESTINE ABSORPTION; INTESTINE EPITHELIUM CELL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FOLIC ACID; FOLIC ACID ANTAGONISTS; GENOTYPE; HUMANS; INTESTINAL ABSORPTION; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); TREATMENT OUTCOME;

EID: 82355170123     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011798062274     Document Type: Article

References (126)

1. Kim, Y. I. Role of folate in colon cancer development and progression. J. Nutr., 2003, 133, 3731S-9S.
2. Smith, A. D.; Kim Y., Refsum, H. Is folic acid good for everyone? Am. J. Clin. Nutr., 2008, 87, 517-33. (Pubitemid 351364531)
3. Jacques, P. F.; Selhub, J.; Bostom, A. G.; Wilson, P. W.; Rosenberg, I. H. The effect of folic acid fortification on plasma folate and total00 homocysteine concentrations. N. Engl. J. Med., 1999, 340(19), 1449-54. (Pubitemid 29220543)
4. Pfeiffer, C. M.; Caudill, S. P.; Gunter, E. W.; Osterloh, J.; Sampson, E. J. Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999-2001-3. Am. J. Clin. Nutr., 2005, 82, 442-50.
5. Holmes, R.; Li, L.; Zheng, Y.; Potter, J.; Baron, J.; Le Marchand, L.; Stern, M.; McKeown-Eyssen, G.; Newcomb, P.; Haile, R.; Limburg, P.; Ulrich, C. Change in use of folic acid-containing supplements after a diagnosis of colorectal cancer. Cancer Prev. Res. 2008;1(7):B128.
6. Holmes, R. S.; Zheng, Y.; Baron, J. A.; Lin Li, McKeown-Eyssen, G.; Newcomb, P. A.; Stern, M. C.; Haile, R. W.; Grady, W. M.; Potter, J. D.; Le Marchand, L.; Campbell, P. T.; Figueiredo, J. C.; Limburg, P. J.; Jenkins, M. A.; Hopper, J. L.; Ulrich, C. M.. Use of Folic Acid-Containing Supplements after a Diagnosis of Colorectal Cancer in the Colon Cancer Family Registry. Cancer. Epidemiol. Biomarkers Prev, 2010, 19(8), 2023-34.
7. Pinedo, H. M.; Peters, G. J. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol., 1988, 6(10), 653-64.
8. Thirion, P. S.; Michiels, S.; Pignon, J. P. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol., 2004, 22, 3766-3775
9. Mini, E.; Trave, F.; Rustum, Y. M.; Bertino, J. R. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol, Ther., 1990, 47(1), 1-19. (Pubitemid 20183305)
10. The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol., 2004, 22, 3766-75.
11. Golfinopoulos, V.; Salanti, G.; Pavlidis, N.; Ioannidis, J. P. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol., 2007, 8, 898-911. (Pubitemid 47488054)
12. Rathkopf, D.; Dickson, M. A.; Feldman, D. R.; Carvajal, R. D.; Shah, M. A.; Wu, N.; Lefkowitz, R.; Gonen, M.; Cane, L. M.; Dials, H. J.; Winkelmann, J. L.; Bosl, G. J.; Schwartz, G. K. Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors. Clin. Cancer Res., 2009, 15(23), 7405-1.
13. Loupakis, F.; Bocci, G.; Pasqualetti, G.; Fornaro, L.; Salvatore, L.; Cremolini, C.; Masi, G.; Danesi, R.; Del Tacca, M.; Falcone, A. Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients. Curr Cancer Drug Targets, 2010, 10(1), 37-45.
14. Masi, G.; Loupakis, F.; Salvatore, L.; Fornaro, L.; Cremolini, C.; Cupini, S.; Ciarlo, A.; Del Monte, F.; Cortesi, E.; Amoroso, D.; Granetto, C.; Fontanini, G.; Sensi, E.; Lupi, C.; Andreuccetti, M.; Falcone, A. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol., 2010, 11(9), 845-52.
15. Köhne, C. H.; Lenz, H. J. AChemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist, 2009, 14(5), 478-88.
16. Hooijberg, J. H.; de Vries, N. A.; Kaspers, G. J. L.; Pieters, R.; Jansen, G.; Peters, G. J. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother Pharmacol., 2006, 58, 1-12.
17. Assaraf, Y. G. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist. Updat., 2006, 9, 227-246. (Pubitemid 44750843)
18. Peters, G. J.; Jansen, G. Folate homeostasis and antiproliferative activity of folates and antifolates. Nutrition, 2001, 17, 737-738. (Pubitemid 32816324)
19. Peters, G. J.; Hooijberg, J. H.; Kaspers, G. J. L.; Jansen, G. Folates and antifolates in the treatment of cancer; role of folic acid supplementation on efficacy of folate and non-folate drugs. Trends in Food Science & Technology, 2005, 16, 289-297. (Pubitemid 40816811)
20. Kim, Y. I. Folate and carcinogenesis: Evidence, mechanisms, and implications. J. Nutr. Biochem., 1999, 10, 66-88.
21. Ulrich, C. M.; Potter, J. D. Folate supplementation to much of a good thing? Cancer Epidemiol. Biomarkers Prev., 2006, 15, 189-93. (Pubitemid 43342163)
22. Kim, YI. Folate a magic bullet or a double edged sword for colorectal cancer prevention? Gut, 2006, 55, 1387-1389.
23. Song, J.; Medline, A.; Mason, J. B.; Gallinger, S.; Kim, Y. I. Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Res., 2000, 60, 5434-40.
24. -/-Msh2-/-mice. Cancer Res, 2000, 60, 3191-3199. (Pubitemid 30407916)
25. Jackson, R. C.; Harrap, K. R. Studies with a mathematical model of folate metabolism. Arch. Biochem. Biophys., 1973, 158(2), 827-841.
26. Moran, R. G.; Werkheiser, W. C.; Zakrzewski, S. F. Folate metabolism in mammalian cells in culture. I Partial characterization of the folate derivatives present in L1210 mouse leukemia cells. J. Biol. Chem., 1976, 25, 251(12), 3569-3575.
27. White, J. C.; Goldman, I. D. Mechanism of action of methotrexate. IV. Free intracellular methotrexate required to suppress dihydrofolate reduction to tetrahydrofolate by Ehrlich ascites tumor cells in vitro. Mol. Pharmacol., 1976, 12(5), 711-719.
28. Seither, R. L.; Trent, D. F.; Mikulecky, D. C.; Rape, T. J.; Goldman, I. D. Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamylates in antifolate action in cells. J. Biol. Chem., 1989, 15, 264(29), 17016-17023. (Pubitemid 19255529)
29. Ratanasthien, K.; Blair. J. A.; Leeming, R. J.; Cooke. W. T.; Melikian, V. Folates in human serum. J. Clin. Pathol., 1974, 27(11), 875-879.
30. Zhao, R.; Matherly, L. H.; Goldman, I. D. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev. Mol. Med., 2009, 28, 11:e4.
31. Ifergan, I.; Assaraf, Y. G. Molecular mechanisms of adaptation to folate deficiency. Vitam. Horm., 2008, 79, 99-143.
32. Qiu, A.; Jansen, M.; Sakaris, A.; Min, S. H.; Chattopadhyay, S.; Tsai, E.; Sandoval, C.; Zhao, R.; Akabas, M. H.; Goldman, I. D. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell, 2006, 1, 127(5), 917-28. (Pubitemid 44792250)
33. Kelly, P.; McPartlin, J.; Goggins, M.; Weir, D. G. Scott, J. M. Unmetabolised folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am. J. Clin. Nutr., 1997, 65, 1790-1795. (Pubitemid 27240695)
34. Lucock, M. D.; Wild, J.; Smithells, R.; Hartley, R. In vivo characterisation of the absorption and biotransformation of pteroylglutamic acid in man: a model for future studies. Biochem. Med. Metab. Biol., 1989, 42, 30-42. (Pubitemid 19237755)
35. Shane, B. In: Folate in health and disease. Ed.; Bailey, L. B. and Dekker, M: New York, 1995, 1-22.
36. Wagner, C. In: Folate in health and disease. Ed.; Bailey, L. B. and Dekker, M.: New York, 1995, 23-42.
37. Stokstad, E. L. R. In: Folic Acid Metabolism in Health and Disease. Picciano, M. F. and Stokstad, E. L. R. Ed.; Wiley-Liss: New York, 1990, 1-21.
38. Sierra, E. E.; Goldman, I. D. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Semin. Oncol., 1999, 26, 2(Suppl 6), 11-23. (Pubitemid 29218023)
39. Zhao, R.; Goldman, I. D. The molecular identity and characterization of a Proton-coupled Folate Transporter-PCFT; biological ramifications and impact on the activity of pemetrexed. Cancer Metastasis Rev., 2007, 26(1), 129-39. (Pubitemid 46452187)
40. Matherly, L. H.; Goldman, I. D. Membrane transport of folates. Vitamin. Horm., 2003, 66, 403-456. (Pubitemid 137640823)
41. Jansen, G.; Pieters, R. The role of impaired transport in (pre) clinical resistance to methotrexate: insights on new antifolates. Drug Resist. Updat., 1998, 1, 211-8.
42. Saier, M. H.; Beatty, J. T.; Goffeau, A.; Harley, K. T.; Heijne, W. H.; Huang, S. C.; Jack, D. L.; Jahn, P. S.; Lew, K.; Liu, J.; Pao, S. S.; Paulsen, I. T.; Tseng, T. T.; Virk, P. S. The major facilitator superfamily. J. Mol. Microbiol. Biotechnol., 1999, 1, 257-279. (Pubitemid 129491947)
43. Salazar, M. D.; Ratnam, M. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev., 2007, 26(1), 141-52. (Pubitemid 46452188)
44. Rothem, L.; Ifergan, I.; Kaufman, Y.; Priest, D. G.; Jansen, G.; Assaraf, Y. G. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. Biochem. J., 2002 1, 367(Pt 3), 741-50. (Pubitemid 35305713)
45. Rothem, L.; Stark, M.; Kaufman, Y.; Mayo, L.; Assaraf, Y. G. Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation. J. Biol. Chem., 2004 2, 279(1), 374-84. (Pubitemid 38044836)
46. Kruh G. D.; Belinsky, M. G. The MRP family of drug efflux pumps. Oncogene, 2003, 22, 7537-7552. (Pubitemid 37487175)
47. McGuire, J. J.; Russell, C. A.; Balinska, M. Human cytosolic and mitochondrial folypolyglutamate synthetase are elettroforetically distinct. J. Biol. Chem., 2000, 275, 13012-13016.
48. Matthews, R. G.; Daubner, S. C. Modulation of methylenetetrahydrofolate reductase activity by S-adenosylmethionine and by dihydrofolate and its polyglutamate analogues. Adv. Enzyme Regul., 1982, 20, 123-31.
49. McGuire, J. J.; Bertino, J. R. Enzymatic synthesis and function of folylpolyglutamates. Mol. Cell Biochem., 1981, 38, 19-48. (Pubitemid 12250045)
50. Shane, B. In: Bailey LB, ed. Folate in health and disease. New York, NY: Marcel Dekker, 1995, 1-22.
51. Lucock, M.; Yates, Z. Folic acid - vitamin and panacea or genetic time bomb? Nature Reviews Genetics, 2005, 6, 235-240. (Pubitemid 40293033)
52. Nijhout, H. F.; Reed, M. C.; Budu, P.; Ulrich, C. M. A mathematical model of the folate cycle: new insights into folate homeostasis. J. Biol. Chem., 2004, 279, 55008-16. (Pubitemid 40066492)
53. Nimec, Z.; Galiven, J. Regulatory aspects of the glutamylation of methotrexate in culture hepatoma cells. Arch. Biochem. Biophys., 1983, 226, 671-680. (Pubitemid 13022701)
54. Johnson, T. B.; Nair, M. G.; Galivan, J. Role of folylpolyglutamate synthetase in the regulation of methotrexate polyglutamate formation in H35 hepatoma cells. Cancer Res., 1988, 48, 2426-2431.
55. Assaraf, Y. G.; Goldman, I. D.. Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate resistant mammalian cells. J. Biol. Chem., 1997, 272, 17460-17466. (Pubitemid 27311177)
56. Jansen, G.; Mauritz, R.; Drori, S.; Sprecher, H.; Kathmann, I.; Bunni, M.; Priest, D. G.; Noordhuis, P.; Schornagel, J. H.; Pinedo, H. M.; Peters, G. J.; Assaraf, Y. G.. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J. Biol. Chem., 1998, 273, 30189-30198. (Pubitemid 28545482)
57. van der Wilt, C. L.; Backus, H. H.; Smid, K.; Comijn, L.; Veerman, G.; Wouters, D.; Voom, D. A.; Priest, D. G.; Bunni, M. A.; Mitchell, F.; Jackman, A. L.; Jansen, G.; Peters, G. J.. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res., 2001, 61, 3675-3681. (Pubitemid 32694979)
58. Zhao, R.; Gao, F.; Goldman, I. D. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem. Pharmacol., 2001, 61, 857-865. (Pubitemid 32245569)
59. Stark, M.; Wichman, C.; Avivi, I.; Assaraf, Y. G. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood, 2009, 30, 113(18), 4362-4369.
60. Mauritz, R.; Peters, G. J.; Priest, D. G.; Assaraf, Y. G.; Drori, S.; Kathmann, I.; Noordhuis, P.; Bunni, M. A.; Rosowsky, A.; Schornagel, J. H.; Pinedo, H. M.; Jansen, G. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem. Pharmacol., 2002, 15, 63(2), 105-115. (Pubitemid 34158809)
61. Liani, E.; Rothem, L.; Bunni, M. A.; Smith, C. A.; Jansen, G.; Assaraf, Y. G. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylationdependent novel antifolates in multiple human leukemia sublines. Int. J. Cancer, 2003, 20, 103(5), 587-599. (Pubitemid 36091461)
62. Frosst, P.; Blom, H. J.; Milos, R.; Goyette, P.; Sheppard, C. A.; Matthews, R. G.; Boers, G. J.; den Heijer, M.; Kluijtmans, L. A.; van den Heuvel, L. P.; et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 1995, 10(1), 111-113.
63. Goyette, P.; Sumner, J. S.; Milos, R.; Duncan, A. M.; Rosenblatt, D. S.; Matthews, R. G.; Rozen, R. Human methylenetetrahydrofolate reductase: isolation of cDNA mapping and mutation identification. Nat. Genet., 1994, 7(2), 195-200. (Pubitemid 24174661)
64. Bagley, P. J.; Selhub, J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc. Natl. Acad. Sci. USA, 1998, 95, 13217-13220. (Pubitemid 28509551)
65. Duthie, S. J.; Hawdon, A. DNA instability (strand breakage, uracil misincorporation, and defective repair) is increased by folic acid depletion in human lymphocytes in vitro. FASEB J., 1998, 12, 1491-1497. (Pubitemid 28506718)
66. Ma, J.; Stampfer, M. J.; Giovannucci, E.; Artigas, C.; Hunter, D. J.; Fuchs, C.; Willett, W. C.; Selhub, J.; Hennekens, C. H.; Rozen, R. Methylenetetrahydrofolate reductase polymorphism, dietary interractions and risk of colorectal cancer. Cancer Res., 1997, 57, 1098-1102. (Pubitemid 27138608)
67. Prasmusinto, D.; Skrablin, S.; Hofstaetter, C.; Fimmers, R.; van der Ven, K. The methylenetetrahydrofolate reductase 677 C->T polymorphism and preeclampsia in two populations. Obstet. Gynecol., 2002, 99(6), 1085-1092. (Pubitemid 34621236)
68. Longley, D. B.; Harkin, D. P.; Johnston, P. G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer, 2003, 3(5), 330-338. (Pubitemid 37328853)
69. Sohn, K. J.; Croxford, R.; Yates, Z.; Lucock, M.; Kim, Y. I. Effect of the Methylenetetrahydrofolate Reductase C677T Polymorphism on Chemosensitivity of Colon and Breast Cancer Cells to 5-Fluorouracil and Methotrexate. J. Natl. Cancer Inst., 2004, 96, 134-44. (Pubitemid 38195904)
70. Kim, Y. I. Role of the MTHFR polymorphisms in cancer risk modification and treatment. Future Oncol., 2009, 5(4), 523-542.
71. Mauritz, R.; Peters, G. J. Pharmacogenetics of colon cancer and potential implications for 5-fluorouracil-based chemotherapy. Current Pharmacogenomics, 2006, 4, 57-67.
72. Peters, G. J.; Honeywell, R. J.; Leon, L. G.; Van Groeningen, C. J.; Jansen, G.; Ylstra, B.; Meijer, G. A.; Giovannetti, E. Role of pharmacodynamic, pharmacogenetic and pharmacogenomic biomarkers of cancer chemotherapy with antifolates. Pteridines, 2009, 20, 115s-127s.
73. Vossen CY, Hoffmeister M, Chang-Claude JC, Rosendaal FR, Brenner H. Clotting Factor Gene Polymorphisms and Colorectal Cancer Risk. J. Clin. Oncol., 2011 Mar. 21 [Epub ahead of print]
74. Cohen, V.; Panet-Raymond, V.; Sabbaghian, N.; Morin, I.; Batist, G.; Rozen, R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res., 2003, 9(5), 1611-5. (Pubitemid 36554583)
75. Etienne, M. C.; Formento, J. L.; Chazal, M.; Francoual, M.; Magné, N.; Formento, P.; Bourgeon, A.; Seitz, J. F.; Delpero, J. R.; Letoublon, C.; Pezet, D.; Milano, G. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics, 2004 14(12), 785-792. (Pubitemid 40054334)
76. Jakobsen, A.; Nielsen, J. N.; Gyldenkerne, N.; Lindeberg, J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J. Clin. Oncol., 2005, 1, 23(7), 1365-1369.
77. Marcuello, E.; Altés, A.; Menoyo, A.; Rio, E. D.; Baiget, M. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother. Pharmacol., 2006, 57(6), 835-840.
78. Derwinger, K.; Wettergren, Y.; Odin, E.; Carlsson, G.; Gustavsson, B. A Study of the MTHFR Gene Polymorphism C677T in Colorectal Cancer. Clinical Colorectal Cancer, 2009, 1, 43-48.
79. Sharma, R.; Hoskins, J. M.; Rivory, L. P.; Zucknick, M.; London, R.; Liddle, C.; Clarke, S. J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin. Cancer Res., 2008, 1, 14(3), 817-825. (Pubitemid 351231165)
80. Underhill, C.; Goldstein, D.; Gorbounova, V. A.; Biakhov, M. Y.; Bazin, I. S.; Granov, D. A.; Hossain, A. M.; Blatter, J.; Kaiser, C.; Ma, D. A. Randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. Oncology, 2007, 73, 9-20. (Pubitemid 351465595)
81. Zintzaras, E.; Ziogas, D. C.; Kitsios, G. D, Papathanasiou, A. A, Lau, J. Raman, G. MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. Pharmacogenomics, 2009, 10(8), 1285-1294.
82. Afzal S, Gusella M, Vainer B, Vogel U, Andersen JT, Broedbaek K, Petersen M, Jiminez-Solem E, Bertolaso L, Barile C, Padrini R, Pasini F, Jensen SA, Enghusen Poulsen H. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy treated colorectal cancer patients. Clin. Cancer Res., 2011 Apr. 6 [Epub ahead of print].
83. Giovannetti, E.; Ugrasena, D. G.; Supriyadi, E.; Vroling, L.; Azzarello, A.; De Lange, D.; Peters, G. J.; Veerman, A. J. P.; Cloos, J. Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia. Leuk. Res., 2008, 32, 19-24. (Pubitemid 350100830)
84. Sohn, K. J.; Croxford, R.; Yates, Z.; Lucock, M.; Kim, Y. I. Effect of the Methylenetetrahydrofolate Reductase C677T Polymorphism on Chemosensitivity of Colon and Breast Cancer Cells to 5-Fluorouracil and Methotrexate. J. Natl. Cancer Inst., 2004, 96, 134-44. (Pubitemid 38195904)
85. Stevenson, J. P.; Redlinger, M.; Kluijtmans, L. A.; Sun, W.; Algazy, K.; Giantonio, B.; Haller, D. G.; Hardy, C, Whitehead, A. S.; O'Dwyer, P. J. Phase I Clinical and Pharmacogenetic Trial of Irinotecan and Raltitrexed Administered Every 21 Days to Patients With Cancer. J. Clin. Oncol., 2001, 19(20), 4081-4087. (Pubitemid 32976696)
86. Deeley, R. G.; Westlake, C.; Cole, S. P. Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev., 2006, 86, 849-899. (Pubitemid 44033384)
87. Assaraf, Y. G.; Rothem, L.; Hooijberg, J. H.; Stark, M.; Ifergan, I.; Kathmann, I.; Dijkmans, B. A.; Peters, G. J.; Jansen, G. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J. Biol. Chem., 2003, 28, 278(9), 6680-6686. (Pubitemid 36800654)
88. Lemos, C.; Jansen, G.; Peters, G. J. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br. J. Cancer, 2008, 98, 857-862. (Pubitemid 351341599)
89. Sarkadi, B.; Homolya, L.; Szakacs, G.; Varadi, A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev., 2006, 86, 1179-1236. (Pubitemid 44521651)
90. Ifergan, I.; Shafran, A.; Jansen, G.; Hooijberg, J. H.; Scheffer, G. L.; Assaraf, Y. G. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J. Biol. Chem., 2004, 11, 279(24), 25527-25534. (Pubitemid 38756812)
91. Shafran, A.; Ifergan, I.; Bram, E.; Jansenm G.; Kathmannm I.; Peters, G. J.; Robey, R. W.; Bates, S. E.; Assaraf, Y. G. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res, 2005, 15, 65(18), 8414-8422. (Pubitemid 41330608)
92. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2, 48-58. (Pubitemid 37328807)
93. Assaraf, Y. G.; Molina, A.; Schimke, R. T. Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate. J. Biol. Chem., 1989, 5, 264(31), 18326-18334. (Pubitemid 19277572)
94. Assaraf, Y. G.; Molina, A.; Schimke, R. T. Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. J. Natl. Cancer Inst., 1989, 15, 81(4), 290-294. (Pubitemid 19060770)
95. Borst, P.; Oude Elferink, R. O.; Mammalian ABC transporters in health and disease. Ann. Rev. Biochem., 2002, 71, 537-592. (Pubitemid 34800230)
96. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M.; Targeting multidrug resistance in cancer. Nat. Rev. Drug Disc., 2006, 5, 219-234. (Pubitemid 43336035)
97. Doyle, L. A.; Ross, D. D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene, 2003, 22, 7340-7358. (Pubitemid 37487163)
98. Kruh, G. D.; Belinsky, M. G. The MRP family of drug efflux pumps. Oncogene, 2003, 22, 7537-7552. (Pubitemid 37487175)
99. Chen, Z. S.; Robey, R. W.; Belinsky, M. G.; Schvaveleva, I.; Ren, X. O.; Sugimoto, Y.; Ross, D. D.; Bates, S. E.; Kruh, G. D. Cancer Res., 2003, 63, 4048-4054.
100. Volk, E. L.; Schneider, E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res., 2003, 63, 5538-5543. (Pubitemid 37139875)
101. Hooijberg, J. H.; Broxterman, H. J.; Kool, M.; Assaraf, Y. G.; Peters, G. J.; Noordhuis, P.; Scheper, R. J.; Borst, P.; Pinedo, H. M.; Jansen, G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res., 1999, 1, 59(11), 2532-2535. (Pubitemid 29269093)
102. Hooijberg, J. H.; Jansen, G.; Assaraf, Y. G.; Kathmann, I.; Pieters, R.; Laan, A. C.; Veerman, A. J. P.; Kaspers, G. J. L.; Peters, G. J. Folate concentration dependent transport activity of the multidrug resistance protein 1 (ABCC1). Biochem. Pharmacol., 2004, 67, 1541-1548. (Pubitemid 38388216)
103. Assaraf, Y. G.; Rothem, L.; Hooijberg, J. H.; Stark, M.; Ifergan, I.; Kathmann, I.; Dijkmans, B. A.; Peters, G. J.; Jansen, G. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J. Biol. Chem., 2003, 28, 278(9), 6680-6686. (Pubitemid 36800654)
104. Stark, M.; Rothem, L.; Jansen, G.; Scheffer, G. L.; Goldman, I. D.; Assaraf, Y. G. Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Mol. Pharmacol., 2003, 64(2), 220-227. (Pubitemid 36909985)
105. Lemos, C.; Kathmann, I.; Giovannetti, E.; Dekker, H.; Scheffer, G. L.; Calhau, C.; Jansen, G.; Peters, G. J. Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells. Int. J. Cancer, 2008, 1, 123(7), 1712-1720.
106. Lemos, C.; Kathmann, I.; Giovannetti, E.; Calhau, C.; Jansen, G.; Peters, G. J. Impact of cellular folate status and epidermal growth factor receptor-expressing cells on BCRP/ABCG2 mediated resistance to gefitinib and erlotinib. Br. J. Cancer, 2009, 100, 1120-1127.
107. Mogi, M.; Yang, J.; Lambert, J. F. Colvin, G. A.; Shiojima, I.; Skurk, C.; Summer, R.; Fine, A.; Peter, J. Quesenberry, and Kenneth Walsh. Akt Signaling Regulates Side Population Cell Phenotype via Bcrp1 Translocation. J. Biol. Chem., 2003, 278(40), 39068-39075. (Pubitemid 37221810)
108. Porcelli, L.; Lemos, C.; Peters, G. J.; Paradiso, A.; Azzariti, A. Intracellular Trafficking of MDR Transporters and Relevance of SNPs. Curr. Top. Med. Chem., 2009, 9(197), 208-197.
109. Lemos, C.; Kathmann, I.; Giovannetti, E.; Beliën, J. A. M.; Scheffer, G. L.; Calhau, C.; Jansen, G.; Peters, G. J. Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins. Mol. Cancer Ther., 2009, 8(3), 655-664.
110. Assaraf, Y. G. Molecular basis of antifolate resistance. Cancer Metastasis Rev., 2007, 26, 153-181. (Pubitemid 46452189)
111. Jansen, G.; Barr, H.; Kathmann, I.; Bunni, M. A.; Priest, D. G.; Noordhuis, P.; Peters, G. J.; Assaraf, Y. G. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: Role of increased folylpolyglutamylation, expanded folate pools and intralysosomal drug sequestration. Mol. Pharmacol., 1999, 5, 761-769. Porcelli et al. (Pubitemid 29165442)
112. Tse, A.; Moran, R. G. Cellular folates prevent polyglutamylation of 5, 10-dideazatetrahydrofolate. A novel mechanism of resistance to antimetabolites. J. Biol. Chem., 1998, 273, 25953-25960.
113. Backus, H. H. J.; Pinedo, H. M.; Wouters, D.; Padrón, J. M.; Molders, N.; van der wilt, C. L.; van Groeningen, C. J.; Jansen, G.; Peters, G. J. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int. J. Cancer, 2000, 87, 771-778. (Pubitemid 30660553)
114. Chattopadhyay, S.; Tamari, R.; Min, S. H.; Zhao, R.; Tsai, E.; Goldman, D. I. Commentary: A Case for Minimizing Folate Supplementation in Clinical Regimens with Pemetrexed Based on the Marked Sensitivity of the Drug to Folate Availability. The Oncologist, 2007, 12, 808-815. (Pubitemid 47328224)
115. van der Wilt, C. L.; Peters, G. J. New targets for pyrimidine antimetabolites for the treatment of solid tumours. 1: Thymidylate synthase. Pharm. World Sci., 1994, 16, 84-103. (Pubitemid 24142451)
116. van der Wilt, C. L.; Pinedo, H. M.; Cloos, J.; Noordhuis, P.; Smid, K.; Peters, G. J. Effect of folinic acid on 5-fluorouracil activity and expression of thymidylate synthase. Sem. Oncol., 1992, 19(3), 16-25.
117. van der Wilt, C. L.; Smid, K.; Pinedo, H. M.; Peters, G. J. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by addition of leucovorin in murine colon tumors. Cancer Res., 1992, 52, 4922-4928.
118. The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol., 2004, 22, 3766-3775.
119. Poon, M. A.; O'Connell, M. J.; Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol., 1989, 7, 1407-1418. (Pubitemid 19245110)
120. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 1992, 10, 896-903.
121. Sadahiro, S.; Suzuki, T.; Maeda, Y.; Tanaka, A.; Ogoshi, K.; Kamijo, A.; Murayama, C.; Tsukioka, S.; Sakamoto, E.; Fukui, Y.; Oka, T. Molecular determinants of folate levels after leucovorin administration in colorectal cancer. Cancer Chemother. Pharmacol., 2010 65(4), 735-742.
122. Schlemmer M, Kuehl M, Schalhorn A, Rauch J, Jauch KW, Hentrich M. Tissue Levels of Reduced Folates in Patients with Colorectal Carcinoma After Infusion of Folinic Acid at Various Dose Levels. Clin. Cancer Res., 2008, 14(23), 7930-7934.
123. Peters, G. J.; van der Wilt, C. L.; Van Groeningen, C. J.; Meijer, S.; Smid, K.; Pinedo, H. M. Thymidylate synthase inhibition after administration of 5-fluorouracil with or without leucovorin; implications for treatment with 5-fluorouracil. J. Clin. Oncol., 1994, 12, 2035-2042. (Pubitemid 24356018)
124. Peters, G. J.; van der Wilt, C. L.; Van Groeningen, C. J.; Priest, D. G.; Schmitz, J.; Smid, K.; Meijer, S.; Noordhuis, P.; Hoekman, K.; Pinedo, H. M. In: Chemistry and Biology of Pteridines and Folates 1997 Ed.; W. Pfleiderer & H. Rokos, Blackwell Science: Berlin, 1997, 145-150.
125. Deeley, R. G.; Westlake, C.; Cole, S. P. Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev., 2006, 86, 849-899. (Pubitemid 44033384)
126. Odin, E.; Wettergren, Y.; Nilsson, S.; Willén, R.; Carlsson, G.; Spears, C. P.; Larsson, L.; Gustavsson, B. Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin. Cancer Res., 2003, 9, 6012-6019. (Pubitemid 38018088)